Skip to main content

GenMark Paying ALL up to $3M as Part of Platform Development Deal

NEW YORK (GenomeWeb News) – GenMark Diagnostics will pay Advanced Liquid Logic up to $3 million as part of a deal originally announced last month, it said in its Form 10-Q filed with the US Securities and Exchange Commission on Thursday.

The Carlsbad, Calif.-based company disclosed that it has agreed to pay up to $3 million to ALL in license fees, contingent milestone payments, and an equity investment in connection with an agreement between the firms to develop an all-electronic, fully integrated in vitro diagnostic platform.

ALL, based in Durham, NC, develops microfluidics products for newborn screening and genomic sample preparation.

GenMark, which this week announced first-quarter revenues jumped 185 percent year over year, also disclosed in its SEC document that during Q1 it acquired exclusive and non-exclusive licenses for various microfluidic technologies for a total of $400,000, which will be amortized over a 10-year period of expected use.

In addition to the ALL agreement, GenMark reached a deal with PerkinElmer during the first quarter to license its microfluidics patent portfolio. GenMark did not say in the SEC filing whether the $400,000 is tied to the PerkinElmer agreement.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.